<DOC>
	<DOCNO>NCT00006121</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness oxaliplatin treat woman advance metastatic breast cancer respond previous chemotherapy .</brief_summary>
	<brief_title>Oxaliplatin Treating Women With Advanced Metastatic Breast Cancer That Has Not Responded Previous Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine therapeutic activity oxaliplatin patient advance metastatic breast cancer follow failure anthracycline/taxane base chemotherapy . - Determine objective response , duration response , time progression patient treat regimen . - Determine acute side effect regimen patient . OUTLINE : This multicenter study . Patients receive oxaliplatin IV 2 hour day 1 . Treatment continue every 3 week absence disease progression unacceptable toxicity . Patients follow every 6 week disease progression every 3 month survival . PROJECTED ACCRUAL : A total 27-40 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced metastatic breast cancer Bidimensionally measurable disease At least one lesion least 2 cm one dimension CT scan MRI Must fail prior anthracycline/taxane base chemotherapy define one following : Stage IV disease treat anthracycline/taxane combination first line therapy advance metastatic disease Stage IV disease treat first line anthracycline therapy second line taxane therapy advance metastatic disease Any adjuvant treatment anthracycline base therapy follow anthracycline/taxane combination first line therapy advance metastatic disease Any adjuvant therapy anthracycline base therapy follow first line anthracycline base therapy second line taxane base therapy advance metastatic disease Adjuvant anthracycline base therapy follow relapse 6 month treat anthracycline/taxane combination first line therapy first line anthracycline base therapy second line taxane base therapy advance metastatic disease Adjuvant anthracycline base therapy follow relapse within 6 month treat first line taxane base therapy advance metastatic disease Disease progression within 6 month last taxane base chemotherapy No brain metastases Hormonal receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count great 2,000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) Alkaline phosphatase transaminases great 2.5 time ULN ( great 5 time ULN case liver metastasis ) Renal : Creatinine le 1.25 time ULN Cardiovascular : LVEF least 50 % prior total dose doxorubicin 550 mg/m2 great , epirubicin 900 mg/m2 great , pirarubicin 700 mg/m2 great No prior active congestive heart failure , myocardial infarction , angina No uncontrolled hypertension arrhythmia Other : No unstable systemic disease No active infection No grade 2 great peripheral neuropathy No psychological , familial , sociological , geographical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior high dose chemotherapy hematopoietic rescue No concurrent immunotherapy No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF ) prevention neutropenia Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy At least 1 prior taxane base chemotherapy advance metastatic disease No prior high dose chemotherapy hematopoietic rescue No prior platinum base chemotherapy No prior taxane chemotherapy docetaxel paclitaxel No prior adjuvant neoadjuvant therapy taxane/anthracycline base combination chemotherapy Endocrine therapy : No concurrent steroids except case allergy prevention , emesis prophylaxis , long term treatment 3 month prior study No concurrent hormonal anticancer therapy Radiotherapy : No prior radiotherapy study site unless evidence disease progression Concurrent local radiotherapy allow pain relief Surgery : At least 4 week since prior major surgery Other : At least 4 week since prior anticancer and/or investigational drug No concurrent bisphosphonates unless start least 2 month prior study No concurrent anticancer therapy No concurrent experimental drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage III breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>